Not only did the COVID-19 pandemic bring lockdown rules and increased safety protocols, it also led to delays, reconfigurations, limited patient access, and other restrictions for life scie
Andy Graves and Dr Clare Moloney of IQVIA discuss how the COVID-19 pandemic accelerated the adoption of digital patient services and how future deployment alongside traditional methods coul
There is a bright future ahead for open innovation in pharma, as Almirall executive vice-president, research and development chief scientific officer Karl Ziegelbauer explains.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.